FDA Approves Forest’s Teflaro For Bacterial Infections Including MRSA

The Food and Drug Administration Oct. 29 approved Teflaro (ceftaroline fosamil), an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).

Teflaro, which is marketed by New York-based Forest Laboratories, is an antibacterial agent in a class of drugs known as cephalosporins, which act by interfering with the bacterial cell wall, FDA said.

CABP is a bacterial infection that develops in the lungs of patients who are exposed to the bacteria in their normal environment, and not in the hospital, the agency said. ABSSSI ...